IQ-UIP

by Imbio  · Based in United States → — AI-powered medical imaging analysis for personalized lung and cardiothoracic care, transforming standard images into life-changing insights.
Pulmonology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

Imbio, now a subsidiary of 4DMedical, develops advanced AI-powered medical imaging analysis solutions designed to transform standard medical images into rich visual maps and quantitative reports. The company leverages machine learning and artificial intelligence to provide physicians with detailed data for improved patient care, spanning from screening and diagnosis to procedure planning and therapy tracking. Imbio’s solutions are fully automated, integrating seamlessly into existing clinical workflows to deliver comprehensive quantitative analysis and 3D visualization without adding extra work for radiologists.

Specifically, IQ-UIP is a computer-aided software that utilizes an artificial intelligence algorithm to automatically analyze qualifying chest computed tomography (CT) scans. Its primary function is to identify findings suspicious for the radiological Usual Interstitial Pneumonia (UIP) pattern. The device generates a summary output to report positive findings, operating in parallel to and separate from the standard radiological image interpretation. This tool assists Interstitial Lung Disease (ILD) clinics in identifying patients with radiological UIP within their hospital systems, aiding specialists in the review of medical images. Imbio’s technology aims to enhance diagnostic accuracy and streamline the assessment of complex lung conditions.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered analysis of chest CT scans
  • Identification of Usual Interstitial Pneumonia (UIP) patterns
  • Automated image classification
  • Generates summary reports for specialists
  • Integrates into existing clinical workflows (parallel processing)
  • Provides quantitative analysis and 3D visualization
  • DICOM input/output compatibility
  • Web-based portal for results
  • Fully automated, no user input required for processing
  • Supports population health screening for incidental UIP detection

Use Cases

  • Notifying ILD specialists of potential UIP findings
  • Assisting with the review of medical images for Interstitial Lung Disease (ILD)
  • Population health screening for incidental UIP detection on chest CTs
  • Aiding ILD diagnosis and therapy response assessment
  • Supporting clinical trials and academic research
  • Integration into lung cancer screening programs

What Physicians Need to Know

Evidence Base
IQ-UIP references the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines for the definition of radiological Usual Interstitial Pneumonia (UIP) pattern. Summary reports generated by the software include a clinical guideline reference for informational purposes.
Clinical Validation Studies
IQ-UIP has demonstrated 90.2% sensitivity and 91.5% specificity for detecting UIP patterns on qualifying CT scans, with performance comparable to expert thoracic radiologist panels. It received FDA 510(k) clearance in 2024. The deep learning model was developed using anonymized, multi-center, retrospective CT scans. A related machine learning classifier (Fibresolve) showed 67% sensitivity and 90% specificity for IPF diagnosis in a validation set.
Alert Fatigue Management
The software passively notifies specialists at Interstitial Lung Disease (ILD) Centers of radiological findings suggestive of UIP. An IQ-UIP Report is automatically generated and added to a designated worklist, operating in parallel to the standard of care radiological image interpretation, thus not interfering with the primary radiology workflow. The system can also filter out scans from patients with previously identified UIP to reduce unnecessary notifications.
Guideline Update Frequency
The tool references the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines. While the software's internal update frequency for guidelines is not explicitly stated, these external guidelines are periodically revised and updated by scientific societies.
Clinical Workflow Integration
IQ-UIP is designed for seamless integration into existing clinical workflows. It automatically analyzes DICOM format CT images and sends outputs to Imbio's web-based Portal or commercial distribution partners' applications, generating a report on a dedicated worklist. Deployment options include Imbio Cloud, an on-premise Imbio Enterprise solution, or integration through channel partners like Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, or Flywheel. Results are intended to be 'First-Read Ready' and accessible via PACS.
Decision Audit Trail
The system allows clinicians to mark a patient's review as 'complete' if they disagree with the analysis, implying a record of the review process. However, detailed information about a comprehensive decision audit trail is not explicitly provided.
Physician Tip

IQ-UIP is a powerful AI-driven tool for identifying radiological UIP patterns in CT scans, which can significantly expedite the referral of patients to ILD specialists. Remember that it functions as a notification system, not a diagnostic tool; final diagnoses and treatment decisions remain the responsibility of the multidisciplinary team after reviewing the full clinical context and original images. Leverage its high sensitivity and specificity to enhance early detection, especially in incidental findings, but always exercise professional judgment and integrate its output with comprehensive patient information. Utilize the worklist application to streamline follow-up for flagged cases and be aware of the option to mark cases as 'review complete' if the AI's findings are not clinically concordant.

IQ-UIP offers flexible integration options, including cloud-based, on-premise enterprise solutions, and partnerships with major AI platforms and PACS vendors (e.g., Nuance, Aidoc, Siemens Syngo.via, TeraRecon). This ensures it can be seamlessly incorporated into diverse hospital IT infrastructures without altering primary radiology workflows. The system imports DICOM images and exports quantitative reports and 3D DICOM series directly into the patient study, making results readily available within existing PACS systems.

Details

Category Clinical Decision Support & Reference, Radiology & Imaging AI
Pricing Contact for pricing — Subscription-based; Based on number of analyses, number of installations.
DeploymentCloud-based (AWS) with on-premise bridge; Fully on-premise (VMware); Available via partner platforms (e.g., Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel).
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Imbio IQ-UIP is a computer-aided software indicated for use in notifying specialists associated with Interstitial Lung Disease (ILD) Centers of radiological findings suggestive of radiological Usual Interstitial Pneumonia (UIP) in non-contrast, chest CT scans of adults. It was FDA-cleared in 2024 under K242467.
Integrations
EHR Not specified
Specialties Pulmonology, Radiology

What the Web Says

IQ-UIP, developed by Imbio (a subsidiary of 4DMedical), is an AI-powered software designed to enhance the detection of Usual Interstitial Pneumonia (UIP) from non-contrast chest CT scans. It received FDA clearance in 2024 and aims to improve the timeliness and accuracy of UIP diagnosis, which is often misdiagnosed. The software analyzes images using deep learning to identify UIP patterns like subpleural fibrosis and honeycombing, providing summary reports to specialists.

Overall: Positive

Strengths

  • Accurate and expert-level performance in UIP detection (90.2% sensitivity and 91.5% specificity).
  • Significantly improves efficiency and timeliness of UIP identification.
  • Leverages AI to automatically screen CT scans and flag patients for specialty referral, improving access to timely expert care.
  • Helps overcome diagnostic delays and high misdiagnosis rates associated with UIP.
  • Integrates with inspiratory CT scans for instant analysis.
  • Provides automated referral workflows for specialists.

Limitations

  • The software is intended for passive notification and informational purposes only, not as a diagnostic device, and clinicians are responsible for final determinations.
  • Does not alter original medical images or interface directly with CT equipment.
  • Does not provide image viewing capabilities or route images.
  • Does not flag or prioritize cases within the standard radiology workflow.
  • No specific reviews from physicians, healthcare IT, tech reviewers, G2, or Capterra for IQ-UIP were found, only general information about the product and related companies.

Based on reviews from: 4DMedical (IQ-UIPu2122 - 4DMedical), Diagnostic Imaging (FDA Clears CT-Based AI Software for Enhanced Detection of Usual Interstitial Pneumonia), 4DMedical (IQ-UIP - 4DMedical), accessdata.fda.gov (K242467 Trade/Device Nam), Reddit (I was diagnosed with idiopathic interstitial lung disease. : r/Radiology), 4DMedical (IMBIO IQ-UIP USER MANUAL), Reddit (Former triathlete but now diagnosed with UIP ! : r/ILD), Healthgrades (Best Interstitial Lung Disease Doctors in Surprise, AZ), Healthgrades (Best Interstitial Lung Disease Doctors in Sarasota, FL), Reddit (Safe or not? IQ Test Scam), G2 (Capterra Pros and Cons | User Likes & Dislikes), Reddit (Scammed by iq-institute org - fraudulent company), MediFind (The 20 Best Interstitial Lung Disease Doctors in The United States), G2 (UiPath Agentic Automation Reviews 2026: Details, Pricing, & Features), Capterra (ClientIQ Reviews 2026. Verified Reviews, Pros & Cons), Reddit (Shady Scam Review: IQ Institute), Indeed.com (Working at Healthcare IQ: Employee Reviews), G2 (IQ CRM Reviews 2026: Details, Pricing, & Features), Capterra (Operative IQ Reviews 2026. Verified Reviews, Pros & Cons), G2 (Appvance IQ Reviews & Product Details), Capterra (UiPath Software Pricing, Alternatives & More 2026), JobZone (Motion Picture Projectionist (Mid-Level) vs Tech Reviewer / YouTuber (Mid-Level)), Indeed.com (Working at IQ Technology Solutions: Employee Reviews), G2 (IQVIA Reviews 2026: Details, Pricing, & Features), Capterra (ReviewIQ Software Pricing, Alternatives & More 2026), Indeed.com (Working at IQ Solutions: Employee Reviews), G2 (Case IQ Products | Read 115 Reviews on G2), Indeed.com (Working at Health Quality Innovators: Employee Reviews), rater8 (Integrated Medical Professionals - Reviews by rater8), YouTube (IQ Tech Review)

Last updated: 2026-07-18

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate IQ-UIP

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Market Index
4DMedical receives U.S. FDA clearance for IQ-UIPu2122
4DMedical announced in January 2025 that it received U.S. FDA clearance for its IQ-UIPu2122 product, an AI-driven lung diagnostic tool designed to revolutionize the diagnosis of Usual Interstitial Pneumonia (UIP), a key indicator for Interstitial Pulmonary Fibrosis (IPF). The product had previously received FDA Breakthrough Device Designation in November 2023. [5, 10]
2025-01
Listcorp
4DMedical acquires Imbio and completes equity raising
In December 2023, 4DMedical acquired Imbio, a medical imaging AI company specializing in lung and cardiothoracic conditions. This acquisition integrated Imbio's advanced diagnostic tools, including IQ-UIP, into 4DMedical's product suite, aiming to provide a comprehensive approach to assessing lung disease. [4, 17]
2023-12
accessdata.fda.gov
K242467 Trade/Device Name - IQ-UIP Software
The FDA 510(k) clearance document from December 2024 details IQ-UIP as a computer-aided software that uses an AI algorithm to identify radiological findings suggestive of Usual Interstitial Pneumonia (UIP) in non-contrast chest CT scans. It is intended to notify specialists at Interstitial Lung Disease (ILD) centers and is not a diagnostic device itself. [2, 7]
2024-12
4DMedical
IQ-UIP - 4DMedical
4DMedical's product page highlights IQ-UIPu2122 as state-of-the-art deep learning software designed to classify Usual Interstitial Pneumonia (UIP) and predict patient survival from inspiratory CT scans. It was FDA-cleared in 2024 and boasts high sensitivity and specificity in UIP detection, comparable to expert thoracic radiologists. [3]
2024
The Imaging Wire
Top Radiology Trends for 2025 | FDA's AI Guidance - The Imaging Wire
An article from January 2025 mentions 4DMedical's Imbio subsidiary receiving FDA clearance for IQ-UIP, a solution for identifying imaging findings related to fibrotic lung disease. The algorithm analyzes CT scans to detect interstitial lung disease and generates a quantitative score. [19]
2025-01
4DMedical
Reducing the Burden on Healthcare Systems: The Efficiency of 4D Imaging in Respiratory Medicine - 4DMedical
This April 2025 article discusses how AI-driven algorithms, including those from Imbio, are improving the speed and quality of care in lung disease diagnosis. It highlights how newer technologies enable comprehensive imaging panels to assess multiple lung and cardiovascular conditions from a single scan. [18]
2025-04
Kalkine Media
4DMedical (ASX:4DX) Rallies as Investors Rush Into Healthcare Imaging Stock
A May 2026 article notes 4DMedical's product suite, including IQ-UIP for interstitial lung disease assessment, as a factor in increased investor interest in healthcare imaging stocks. It emphasizes the company's focus on advanced software-based medical solutions. [8]
2026-05
Webull
Leading Cardiopulmonary Imaging into the Next Era - Webull
A September 2025 report highlights the FDA clearance of both CT:VQu2122 and IQ-UIPu2122 as opening significant opportunities for 4DMedical. It notes that IQ-UIP's clearance triggered an earnout payment to the sellers of Imbio. [15]
2025-09

Videos

Product demos, reviews, and walkthroughs for IQ-UIP.

View all on YouTube

Frequently Asked Questions

IQ-UIP is an AI-powered software designed to automatically scan inspiratory CT scans, reliably identifying UIP patterns and flagging patients for timely specialist referral. It immediately highlights key UIP patterns like subpleural fibrosis and honeycombing, providing actionable results directly from standard CT images.
IQ-UIP received FDA 510(k) clearance in 2024, establishing a new standard for pulmonary diagnostics in the U.S. Beyond basic HIPAA compliance, healthcare organizations using AI tools like IQ-UIP must ensure robust data protection protocols, including encryption and strict access controls, and conduct local validation of the AI within their specific clinical context.
Like all AI, IQ-UIP's accuracy is dependent on the data it was trained on; biases or errors in training data can lead to inaccurate predictions. Physicians also express concerns about potential over-reliance on AI, the 'black box' nature of some algorithms, and the need for human oversight to interpret results within a broader clinical context.
IQ-UIP demonstrates expert-level performance in UIP detection, achieving 90.2% sensitivity and 91.5% specificity. This performance is comparable to the diagnostic accuracy of experienced thoracic radiologist panels.
UIP is often difficult to detect, with traditional diagnosis sometimes taking up to two years and having a misdiagnosis rate exceeding 50%. IQ-UIP offers a faster, more consistent, and accurate screening method by automatically identifying UIP patterns, potentially reducing diagnostic delays and improving patient outcomes.
While specific pricing for IQ-UIP is not detailed, diagnostic AI systems typically range from $50,000 to $300,000 for implementation, with larger enterprise integrations costing more. Pricing models can include fixed costs, consumption-based fees, or customized solutions, and regulatory validation pathways can add significant additional costs.
Effective implementation of AI tools like IQ-UIP requires healthcare professionals to receive training on how to operate the system, critically judge its outputs, and adapt existing clinical workflows. Overcoming a lack of knowledge and experience with AI is crucial for successful adoption and maximizing its potential benefits.

Compare IQ-UIP

VS
DeepXray vs IQ-UIP
Clinical Decision Support & Reference Adjacent · 60/100
DeepXray focuses on analyzing X-rays for osteoarthritis and osteoporosis, providing automated measurements and progression monitoring for bone diseases. In contrast, IQ-UIP specializes in analyzing chest CT scans to…
VS
BriefCase vs IQ-UIP
Clinical Decision Support & Reference Adjacent · 60/100
BriefCase and IQ-UIP are adjacent competitors, both utilizing AI for medical imaging analysis in radiology. BriefCase offers a broader AI-powered communication and collaboration solution for various critical findings…

Related Tools

DeepMind (Google)
Google DeepMind
Clinical Decision Support & Reference
AlphaFold is an AI system developed by DeepMind (Google) that accurately predicts protein structures and their interactions, significantly accelerating biological and medical research.
Free for non-commercial use
Tempus AI
Tempus AI
Clinical Decision Support & Reference
Tempus ECG-AI Platform uses artificial intelligence to analyze electrocardiogram data, offering advanced insights for cardiovascular diagnosis and management.
Cortex
Cortex
Clinical Decision Support & Reference
Cortex Workspace is a secure, HIPAA-compliant AI platform designed to streamline healthcare workflows and enhance decision-making for physicians.
Starts free, then $29/month for individual plan (save 10% annually). other plans: enthusiast ($99/month), business ($349/month), enterprise (contact sales).
SureMediks ProView
SureMediks (Rasimo Systems, LLC)
Clinical Decision Support & Reference
SureMediks is an AI-powered clinical decision support and metabolic health platform that automates care workflows for specialists, providing AI-generated patient summaries, automated chart review, and real-time biometric alerts.
SOAP Health
SOAP Health
Clinical Decision Support & Reference
SOAP Health is a Florida-based startup transforming patient intake with AI-powered diagnosis, offering a comprehensive solution that improves diagnosis accuracy and empowers patients and physicians.
Oxipit ChestLink
Oxipit (part of Sectra group)
Clinical Decision Support & Reference
Oxipit ChestLink is the world's first CE Class IIb-certified autonomous AI application for healthy chest X-ray reporting, capable of identifying normal studies with 99.9% sensitivity. It automates the reporting of normal chest X-rays, reducing radiologist workload and improving efficiency.

See all Clinical Decision Support & Reference tools →

More from Imbio

CAC Software
Imbio
Cardiology AI
Imbio's Coronary Artery Calcification (CAC) software is a set of automated image post-processing algorithms designed to help radiologists and cardiologists determine the location and calculate the amount of calcification within the coronary arteries in patients who have undergone a non-contrast, chest computed tomography (CT).
Contact for pricing
Imbio PHA (4.0.0)
Imbio
Cardiology AI
Imbio PHA (4.0.0) is an FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension.
Contact for pricing
Imbio RV/LV Software
Imbio
Cardiology AI
Imbio RV/LV Software is an AI-powered tool that automatically measures right and left ventricular diameters from CTPA scans, providing a ratio to aid in risk stratification for pulmonary conditions like pulmonary embolism.
Subscription-based
Lung Density Analysis
IMBIO
Cardiology AI
IMBIO's Lung Density Analysis is an AI-driven medical imaging software that provides quantitative analysis and 3D visualization of lung conditions from CT scans, aiding in the diagnosis and management of diseases like COPD and emphysema. It offers automated workflows and detailed reports for personalized patient care.
Contact for pricing

View company profile →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.